Last updated: May 23, 2026
SUTENT (sunitinib) Suppliers: Who Manufactures, Supplies APIs, and Provides Finished Dosage Forms
SUTENT is sunitinib in capsule form and is supplied to the U.S. market by Pfizer. Upstream supply chains for the active pharmaceutical ingredient (API) and contract manufacturing of finished dosages vary by market, lot, and regulatory filings, but the principal commercial supplier of record for finished product in the U.S. is Pfizer.
Who supplies SUTENT (sunitinib) finished product in the U.S.?
Pfizer is the listed sponsor/manufacturer for SUTENT in the U.S. through FDA labeling and Orange Book-linked drug product listings. The manufacturer-of-record for the marketed capsule product is typically shown on FDA labeling and Orange Book entries for SUTENT (sunitinib malate).
U.S. label and Orange Book supplier-of-record
- Drug product: SUTENT (sunitinib malate) capsules
- Manufacturer / NDA holder (U.S.): Pfizer
What companies supply SUTENT sunitinib API (active ingredient)?
Sunitinib API supply is sourced from chemical manufacturers and API plants that support global finished product manufacturing and regulatory submissions. API suppliers are typically identified through:
- Drug Substance section of FDA CMC summaries (when available),
- Foreign MF/DMF linkages,
- Plant-level data in inspection histories and submissions.
For SUTENT specifically, the externally visible public data that names API suppliers at the company level is not consistently present in the Orange Book record alone and often requires cross-referencing DMF or CMC content. Without a firm, public, citation-backed list of named API manufacturers for sunitinib malate tied to the U.S. SUTENT product, a complete and accurate “who supplies API” vendor list cannot be produced from the available cited record.
How do DMFs and CMC disclosures identify sunitinib API suppliers?
When sunitinib API is supplied via an FDA Drug Master File (DMF), the supplier name is embedded in the DMF holder and cross-referenced in FDA submissions for the finished dose application. In practice, sourcing is traced via:
- DMF holder legal entity,
- API manufacturing site listed in the DMF,
- Corresponding references in FDA review documents for the NDA/CMC.
Public-facing labeling and Orange Book pages do not always enumerate the underlying DMF holder companies for each marketed lot. As a result, vendor identification must be citation-grade and plant-specific to be defensible.
Which contract manufacturers make SUTENT capsules?
Finished-dose manufacturing for SUTENT is performed by Pfizer and/or Pfizer-designated contract manufacturing organizations depending on the site and market. Public records can show manufacturing locations, but translating that into named “suppliers” (contract manufacturers by legal entity) requires citation-backed mappings from FDA inspections, labeling manufacturing sections, or regulatory submissions.
Without citation-grade plant-to-company mapping for SUTENT in the cited record, a precise contract manufacturing roster cannot be listed.
What is the supply chain for SUTENT capsules vs. alternative dosage forms?
SUTENT is marketed as capsules. Supply chain segmentation usually looks like:
- API: sunitinib malate manufacture (chemical synthesis and salt formation)
- Finished dose: encapsulation, blending, and packaging
- Distribution: wholesalers and logistics for U.S. retail and health systems
SUTENT has had generic and/or alternative branded/country-specific presentations historically, but the supplier discussion here is limited to the marketed branded capsule product.
How do shortages and supply disruptions affect SUTENT suppliers?
When supply disruptions occur, procurement typically shifts among qualified internal sites and approved external facilities where permitted by GMP and change control. The list of “who supplies” can change without changes to the NDA label, because manufacturing sites and packaging sites can be updated via CMC supplements while the label keeps the same NDA holder.
A lot-by-lot supplier change log for SUTENT requires:
- FDA shortage communications,
- lot-level labeling and distribution records,
- CMC supplement histories.
What is the Orange Book status of SUTENT and how does it affect supplier landscape?
Orange Book listings determine the reference product used by generics and the associated patent/exclusivity landscape. That status affects who can supply alternatives:
- Generics compete at the finished-dose level once permitted.
- API procurement still depends on qualified DMF and manufacturing sites.
However, Orange Book listings primarily capture drug product and patent information, not a fully enumerated list of upstream API or all contract manufacturers for the reference product.
Key suppliers summary for SUTENT (sunitinib)
| Supply layer |
Supplier / company (publicly identifiable from cited records) |
What they supply |
| Finished product (U.S.) |
Pfizer |
SUTENT capsules (reference product) |
| API |
Not fully enumerated from cited Orange Book/label record alone |
sunitinib malate API via DMF-linked suppliers |
| Contract manufacturing |
Not fully enumerated from cited record alone |
capsule production and/or packaging depending on site |
Key Takeaways
- Pfizer is the principal supplier of record for SUTENT (sunitinib) capsules in the U.S.
- A complete, named list of API suppliers and contract manufacturers for sunitinib malate cannot be responsibly produced without citation-backed identification of DMF holders and manufacturing sites tied to SUTENT in the cited public record.
- Supplier diversity for API and manufacturing can exist even when the NDA holder and marketed product remain the same.
FAQs
1) Who holds the NDA for SUTENT (sunitinib) in the U.S.?
Pfizer is the NDA holder/sponsor for the branded SUTENT capsules.
2) Are SUTENT API suppliers listed on the Orange Book?
Orange Book records typically focus on drug product entries and patents, not a definitive API supplier roster.
3) Can SUTENT be sourced from multiple manufacturing sites?
Yes. Manufacturing and packaging sites can vary by lot and CMC supplements while maintaining the same branded NDA holder.
4) Do FDA shortage notices reveal SUTENT supplier changes?
Shortage notices may describe supply constraints and affected manufacturers, but they do not consistently provide a complete vendor list.
5) How do generics change the supplier landscape around SUTENT?
They add competing finished-dose manufacturers. The reference product supply chain and NDA-holder manufacturing do not automatically change, but procurement dynamics can.
References
- U.S. Food and Drug Administration. SUTENT (sunitinib malate) drug label and prescribing information.
- U.S. Food and Drug Administration. Drugs@FDA: SUTENT (sunitinib malate) NDA and related product listings.
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations for SUTENT (sunitinib malate).
